0000899243-21-004757.txt : 20210203 0000899243-21-004757.hdr.sgml : 20210203 20210203190045 ACCESSION NUMBER: 0000899243-21-004757 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20210131 FILED AS OF DATE: 20210203 DATE AS OF CHANGE: 20210203 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Harris Matthew Scott CENTRAL INDEX KEY: 0001787762 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-32587 FILM NUMBER: 21588015 MAIL ADDRESS: STREET 1: C/O ALTIMMUNE, INC. STREET 2: 910 CLOPPER ROAD, SUITE 201S CITY: GAITHERSBURG STATE: MD ZIP: 20878 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: Altimmune, Inc. CENTRAL INDEX KEY: 0001326190 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 202726770 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 910 CLOPPER ROAD STREET 2: SUITE 201S CITY: GAITHERSBURG STATE: MD ZIP: 20878 BUSINESS PHONE: 2406541450 MAIL ADDRESS: STREET 1: 910 CLOPPER ROAD STREET 2: SUITE 201S CITY: GAITHERSBURG STATE: MD ZIP: 20878 FORMER COMPANY: FORMER CONFORMED NAME: PHARMATHENE, INC DATE OF NAME CHANGE: 20071016 FORMER COMPANY: FORMER CONFORMED NAME: HEALTHCARE ACQUISITION CORP DATE OF NAME CHANGE: 20050505 4 1 doc4.xml FORM 4 SUBMISSION X0306 4 2021-01-31 0 0001326190 Altimmune, Inc. ALT 0001787762 Harris Matthew Scott C/O ALTIMMUNE, INC. 910 CLOPPER ROAD, SUITE 201S GAITHERSBURG MD 20878 0 1 0 0 Chief Medical Officer Common Stock, par value $0.0001 2021-01-31 4 A 0 968 12.14 A 5037 D Stock Options (option to buy) 16.71 2021-02-01 4 A 0 90000 0.00 A 2031-02-01 Common Stock, par value $0.0001 90000 90000 D Restricted Stock Units 2021-02-01 4 A 0 24664 0.00 A Common Stock, par value $0.0001 24664 24664 D These shares were purchased due to participation by the reporting individual in the issuer's 2019 Employee Stock Purchase Plan ("ESPP"). It pertains to the ESPP purchase period from August 1, 2020 through January 31, 2021. In accordance with the ESPP, these shares were purchased based on 85% of the closing price of the issuer's common stock on January 31, 2021. Twenty-five percent of the shares underlying the option become vested and exercisable on February 1, 2022 and the remaining 75% of the shares underlying the option become vested and exercisable in substantially equal monthly installments over the 36 months following February 2, 2022, subject to the reporting person's continued service through the applicable vesting date. Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of Common Stock, par value $0.0001, when vested. The RSUs become vested and exercisable in substantially equal annual installments over the 4 years following February 2, 2021, subject to the reporting person's continued service through the applicable vesting date, and have no expiration date. On November 13, 2020, the reporting person filed a Form 4 which inadvertently indicated that the reporting person is a director of the issuer. His correct title is Chief Medical Officer. /s/ William Brown, as Attorney-in Fact 2021-02-03